Anemo Labs
Summary
London-based deep tech sensory digitization startup Anemo Labs has secured £700,000 in a Pre-Seed funding round co-led by venture capital firms Zinc and SFC Capital, with additional non-dilutive grant support from Innovate UK.
Summary of transaction details:
- Value: £700,000 Pre-Seed investment (equity co-led by Zinc and SFC Capital, bolstered by Innovate UK grant funding).
- Sector: DeepTech & AI / MedTech / Sensory Digitization & Diagnostics.
- Advisor: Not disclosed.
- Key Entities: Target: Anemo Labs (Anemo Labs Ltd); Co-Lead Investors: Zinc (Zinc VC), SFC Capital; Grant Provider: Innovate UK; Key Founder: Koye Sodipo (Founder & CEO).
- Location: London, UK (HQ).
Note: Founded in 2025 by CEO Koye Sodipo alongside a team of sensor chemistry PhDs and clinical advisors, Anemo Labs is pioneering the digitization of olfaction—the last remaining human sense yet to be effectively digitized into computer-readable data. The company is developing an artificial "Electronic Nose" (e-nose) hardware platform paired with deep learning models to detect, isolate, and classify disease-related Volatile Organic Compounds (VOCs) emitted from biological samples such as urine. Because cellular changes and metabolic shifts emit subtle chemical scent signatures long before physical symptoms appear, Anemo’s non-invasive e-nose provides a continuous, passive screening mechanism for early-stage conditions including Urinary Tract Infections (UTIs) and various cancers. A key technological barrier in olfactory AI is training data; Anemo overcomes this via an automated in-house sampling platform capable of capturing and labeling up to 5,000 scent samples per day. In early performance benchmarking using the industry-standard Sniffin' Sticks protocol, Anemo's classification models achieved an 84.15% accuracy rate across a dozen distinct scent categories. This £700,000 Pre-Seed injection will be deployed to refine core sensor chemistry, expand the automated smell labeling data pipeline, and advance clinical validation trials alongside NHS and academic healthcare partners.
Original Source
View the original press release or news article describing this transaction in full.
Read Original PostAI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in